[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-459521-105":59,"doc-detail-459521-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","outcomes-of-sequential-immune-checkpoint-inhibitor-retreatment-after-atezolizumab-plus-bevacizumab-in-patients-with-unresectable-hepatocellular-carcinoma","Outcomes of Sequential Immune Checkpoint Inhibitor Retreatment After Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma","","Data on sequential immune checkpoint inhibitor (ICI) retreatment following initial atezolizumab plus bevacizumab therapy are limited. This multicenter retrospective study evaluated efficacy and safety of sequential ICI retreatment in patients with unresectable hepatocellular carcinoma (uHCC). Among 835 patients treated with Atez + Bev, 75 underwent ICI retreatment. Three sequential regimens were assessed, with no significant differences in antitumor response. Overall survival was longer in patients achieving at least stable disease. Prior objective response to Atez + Bev predicted disease control, and immune-related adverse events required steroids in 26.7%.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/outcomes-of-sequential-immune-checkpoint-inhibitor-retreatment-after-atezolizumab-plus-bevacizumab-in-patients-with-unresectable-hepatocellular-carcinoma/459521/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/outcomes-of-sequential-immune-checkpoint-inhibitor-retreatment-after-atezolizumab-plus-bevacizumab-in-patients-with-unresectable-hepatocellular-carcinoma/459521.png","ImageObject",300,407,{"name":92,"@type":93},"Jacob","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-30",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study aim regarding sequential ICI retreatment?","Question",{"text":112,"@type":113},"To evaluate the efficacy and safety of sequential immune checkpoint inhibitor retreatment after initial atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What were the sequential retreatment regimens used in the study?",{"text":117,"@type":113},"Participants received one of three regimens: durvalumab plus tremelimumab, retreatment with Atez + Bev, or durvalumab monotherapy.",{"name":119,"@type":110,"acceptedAnswer":120},"What factors were associated with improved outcomes after retreatment?",{"text":121,"@type":113},"Achieving at least stable disease after retreatment was linked to significantly longer overall survival, and prior objective response to Atez + Bev independently predicted disease control after retreatment.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},459521,1790812383,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":4},962084931830,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Journal of  \nGastroenterology and Hepatology  \nORIGINAL ARTICLE-HEPATOLOGY (CLINICAL)  OPEN ACCESS   \nOutcomes of Sequential Immune Checkpoint Inhibitor Retreatment After Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma  \nTakanori Ito1 | Shigeo Shimose2  | Issei Saeki3 | Yasuto Takeuchi4 | Joji Tani5 | Tetsu Tomonari6  | Ryu Sasaki7  | Kyo Sasaki8 | Satoru Kakizaki9  | Takeshi Hatanaka10  | Hideki Iwamoto2,11  | Norikazu Tanabe3 |  \nTakafumi Yamamoto1  | Atsushi Naganuma12 | Tomotake Shirono2 | Yuki Kanayama10 | Hisamitsu Miyaaki7  | Sohji Nishina8 | Tetsuji Takayama6 | Hideki Kobara5 | Motoyuki Otsuka4 | Taro Takami3  | Takumi Kawaguchi2  | Hiroki Kawashima1  | Hepatology InVestigator Experts in Japan (HIVE-J) Study Group  \n1Department of Gastroenterology and Hepatology, Nagoya University Hospital, Nagoya, Japan | 2Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan | 3Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan | 4Department of Gastroenterology, Okayama University Hospital, Okayama, Japan | 5Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Takamatsu, Kagawa, Japan | 6Department of Gastroenterology and Oncology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan | 7Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan | 8Department of Gastroenterology and Hepatology, Kawasaki Medical School, Kurashiki, Japan | 9Department of Clinical Research, NHO Takasaki General Medical Center, Takasaki, Gunma, Japan | 10Department of Gastroenterology, Gunma Saiseikai Maebashi Hospital, Maebashi, Japan | 11Iwamoto Internal Medical Clinic, Kitakyusyu, Japan | 12Department of Gastroenterology, NHO Takasaki General Medical Center, Takasaki, Gunma, Japan  \nCorrespondence: Takanori Ito ([tahkun56@med.nagoya-u.ac.jp](tahkun56@med.nagoya-u.ac.jp))  \nReceived: 18 May 2025 | Revised: 9 October 2025 | Accepted: 17 October 2025  \nFunding: This research was supported by Grants-in-Aid for Scientific Research (grant number 22K15962) and for Research from the National Center for Global Health and Medicine (23A1002) .  \nKeywords: atezolizumab | bevacizumab | immune checkpoint inhibitor | sequential ICI treatment | unresectable hepatocellular carcinoma  \nABSTRACT  \nBackground and Aim: Data on sequential immune checkpoint inhibitor (ICI) retreatment following initial atezolizumab plus bevacizumab (Atez + Bev) are limited. This study aimed to evaluate the efficacy and safety of sequential ICI retreatment in patients with unresectable hepatocellular carcinoma (uHCC) .  \nMethods: Of 835 patients with uHCC treated with Atez + Bev, 75 who underwent ICI retreatment after initial Atez + Bev therapy were included in this multicenter retrospective study that assessed the efficacy and safety of ICIs.  \nResults: The participants received one of three sequential retreatments with ICI regimens: durvalumab plus tremelimumab (n = 58), retreatment with Atez + Bev (n = 15), and durvalumab monotherapy (n = 2). The objective response rates (ORRs)/disease control rates (DCRs) for the initial Atez + Bev and sequential ICI retreatment were 34.7%/89.3% and 18.7%/54.7%, respectively. No significant differences in antitumor response were observed among the three ICI retreatment regimens. Patients who achieved a good antitumor response (≥stable disease) following retreatment showed a significantly longer overall survival. Multivariate  \n\n| Abbreviations: aCTLA-4-Ab, anti-cytotoxic T-lymphocyte-associated antigen 4 antibody; AE, adverse event; ALBI, albumin–bilirubin; ASCO, the American Society of Clinical Oncology; Atez + Bev, atezolizumab plus bevacizumab; BCLC, Barcelona Clinic Liver Cancer; CR, complete response; DCR, disease control rate; Dur + Tre, durvalumab plus tremelimumab; ESMO, the Eur","cbCaiiMHrjutSmtU","https://ap.wps.com/l/cbCaiiMHrjutSmtU","pdf",687196,"English","# Abstract\n## Background and Aim\n## Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What was the study aim regarding sequential ICI retreatment?\",\"answer\":\"To evaluate the efficacy and safety of sequential immune checkpoint inhibitor retreatment after initial atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma.\"},{\"question\":\"What were the sequential retreatment regimens used in the study?\",\"answer\":\"Participants received one of three regimens: durvalumab plus tremelimumab, retreatment with Atez + Bev, or durvalumab monotherapy.\"},{\"question\":\"What factors were associated with improved outcomes after retreatment?\",\"answer\":\"Achieving at least stable disease after retreatment was linked to significantly longer overall survival, and prior objective response to Atez + Bev independently predicted disease control after retreatment.\"}]","Outcomes of Sequential Immune Checkpoint Inhibitor Retreatment After Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma | PDF",1790756123,25]